• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期卵巢癌肿瘤细胞减灭术后的并发症:一项探索综合并发症指数价值及高并发症负担预测因素的单中心分析

Postoperative Complications After Cytoreductive Surgery for Advanced Ovarian Carcinoma: A Single-Center Analysis Exploring the Value of the Comprehensive Complication Index and the Predictors of High Complications Burden.

作者信息

Bianchi Tommaso, Grassi Tommaso, De Ponti Elena, Pecis Cavagna Giorgia, Bombelli Martina, Lugotti Daniele, Testa Filippo, Totis Mauro, Trezzi Gaetano, Landoni Fabio, Fruscio Robert

机构信息

Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.

UO Gynecology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

出版信息

Ann Surg Oncol. 2025 Jun 24. doi: 10.1245/s10434-025-17619-9.

DOI:10.1245/s10434-025-17619-9
PMID:40553357
Abstract

BACKGROUND

The comprehensive complication index (CCI) reflects the overall patient complication burden on a 0-100 scale. This single-institution retrospective analysis explores the accuracy of CCI in describing complications following cytoreductive surgery for advanced high-grade ovarian carcinoma (HGOC) and aims to identify predictive factors of high complication burden.

PATIENTS AND METHODS

In total, 304 patients who underwent cytoreductive surgery for FIGO stage IIIA-IVB HGOC at our institution from 2015 to 2023 were analyzed. Each complication's severity was graded using the Clavien-Dindo classification. The CCI was used to quantify the global complications burden, and patients were stratified into three groups: CCI-low (< 26.2), CCI-intermediate (26 ≤ CCI < 33.7), and CCI-high (≥ 33.7).

RESULTS

Of the 200 patients (65.8%) with at least one complication, 127 (41.8%) were CCI-low, 32 (10.5%) CCI-intermediate, and 41 (13.5%) CCI-high. Median hospitalization duration (p < 0.0001) and readmission rates (p < 0.0001) correlated with CCI categories, reflecting increased CCI scores with greater surgical complexity, as assessed by the Aletti surgical complexity score (SCS). Univariate analysis showed a significant association between CCI-high and FIGO stage, surgical complexity, diaphragmatic procedures, multiple bowel resections, length of surgery and intraoperative blood loss. Multivariate analysis confirmed FIGO stage (odds ratio [OR] 2.57), multiple bowel resections (OR 5.61), and blood loss (OR 1.93) as independent risk factors for high complication burden.

CONCLUSIONS

The CCI is a good descriptor of postoperative complications in patients undergoing cytoreductive surgery for advanced HGOC by integrating both the severity and number of complications into a single, easily usable, and intuitive quantitative score. FIGO stage, multiple bowel resections, and blood loss-but not surgical timing-are independent predictors of a high complication burden.

摘要

背景

综合并发症指数(CCI)在0至100的范围内反映患者总体并发症负担。这项单机构回顾性分析探讨了CCI在描述晚期高级别卵巢癌(HGOC)减瘤手术后并发症方面的准确性,并旨在确定高并发症负担的预测因素。

患者与方法

对2015年至2023年在本机构接受FIGO IIIA-IVB期HGOC减瘤手术的304例患者进行分析。使用Clavien-Dindo分类法对每种并发症的严重程度进行分级。CCI用于量化总体并发症负担,患者被分为三组:低CCI组(<26.2)、中CCI组(26≤CCI<33.7)和高CCI组(≥33.7)。

结果

在200例(65.8%)至少有1种并发症的患者中,127例(41.8%)为低CCI组,32例(10.5%)为中CCI组,41例(13.5%)为高CCI组。中位住院时间(p<0.0001)和再入院率(p<0.0001)与CCI类别相关,反映出随着Aletti手术复杂性评分(SCS)评估的手术复杂性增加,CCI评分升高。单因素分析显示,高CCI组与FIGO分期、手术复杂性、膈肌手术、多次肠切除术、手术时长和术中失血之间存在显著关联。多因素分析证实FIGO分期(比值比[OR]2.57)、多次肠切除术(OR 5.61)和失血(OR 1.93)是高并发症负担的独立危险因素。

结论

CCI通过将并发症的严重程度和数量整合为一个单一、易于使用且直观的定量评分,是晚期HGOC减瘤手术患者术后并发症的良好描述指标。FIGO分期、多次肠切除术和失血——而非手术时机——是高并发症负担的独立预测因素。

相似文献

1
Postoperative Complications After Cytoreductive Surgery for Advanced Ovarian Carcinoma: A Single-Center Analysis Exploring the Value of the Comprehensive Complication Index and the Predictors of High Complications Burden.晚期卵巢癌肿瘤细胞减灭术后的并发症:一项探索综合并发症指数价值及高并发症负担预测因素的单中心分析
Ann Surg Oncol. 2025 Jun 24. doi: 10.1245/s10434-025-17619-9.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
4
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?对于因恶性肿瘤导致骨缺损的患者,在重建下肢节段性切除时,采用带血管游离腓骨移植来增强照射后的自体骨移植,其骨愈合、功能及并发症发生率与无骨缺损且未进行增强的患者相比是否相当?
Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599.
5
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer.氨甲环酸在晚期卵巢癌肿瘤细胞减灭术中减少失血的有效性。
Cochrane Database Syst Rev. 2016 Jan 23;2016(1):CD011732. doi: 10.1002/14651858.CD011732.pub2.
6
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.晚期上皮性卵巢癌初始治疗中,术前新辅助化疗与手术加化疗的比较。
Cochrane Database Syst Rev. 2025 Feb 10;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub7.
7
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.超根治性(广泛)手术与标准手术治疗晚期上皮性卵巢癌的初步细胞减灭术。
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
8
Survival outcomes comparing minimally invasive versus open cytoreductive surgery in recurrent adult-type granulosa cell tumors.复发性成人型颗粒细胞瘤中微创与开放细胞减灭术的生存结果比较
Am J Obstet Gynecol. 2025 Jul;233(1):51.e1-51.e10. doi: 10.1016/j.ajog.2025.01.012. Epub 2025 Jan 15.
9
What Are the Recurrence Rates, Complications, and Functional Outcomes After Multiportal Arthroscopic Synovectomy for Patients With Knee Diffuse-type Tenosynovial Giant-cell Tumors?膝关节弥漫型腱鞘巨细胞瘤患者行多入路关节镜下滑膜切除术的复发率、并发症及功能结局如何?
Clin Orthop Relat Res. 2024 Jul 1;482(7):1218-1229. doi: 10.1097/CORR.0000000000002934. Epub 2023 Dec 28.
10
Surgical cytoreduction for recurrent epithelial ovarian cancer.复发性上皮性卵巢癌的手术细胞减灭术。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008765. doi: 10.1002/14651858.CD008765.pub3.

本文引用的文献

1
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis.晚期卵巢癌的范式转变:广泛的初次细胞减灭术的结果。一项单中心回顾性分析。
Eur J Surg Oncol. 2024 Sep;50(9):108523. doi: 10.1016/j.ejso.2024.108523. Epub 2024 Jun 29.
2
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.ESGO-ESMO-ESP 共识会议关于卵巢癌的建议:病理学和分子生物学以及早期、晚期和复发性疾病。
Ann Oncol. 2024 Mar;35(3):248-266. doi: 10.1016/j.annonc.2023.11.015. Epub 2024 Feb 1.
3
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
新诊断及复发的上皮性卵巢癌:ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Oct;34(10):833-848. doi: 10.1016/j.annonc.2023.07.011. Epub 2023 Aug 17.
4
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update.加速康复外科(ERAS®)协会妇科肿瘤学指南:应对实施挑战——2023 年更新。
Gynecol Oncol. 2023 Jun;173:58-67. doi: 10.1016/j.ygyno.2023.04.009. Epub 2023 Apr 21.
5
Identification of NLE1/CDK1 axis as key regulator in the development and progression of non-small cell lung cancer.鉴定NLE1/CDK1轴是非小细胞肺癌发生发展的关键调节因子。
Front Oncol. 2023 Feb 1;12:985827. doi: 10.3389/fonc.2022.985827. eCollection 2022.
6
Clinical validation and comparison of the Comprehensive Complication Index and Clavien-Dindo classification in predicting post-operative outcomes after cytoreductive surgery in advanced ovarian cancer.全面并发症指数与Clavien-Dindo分类法在预测晚期卵巢癌肿瘤细胞减灭术后结局中的临床验证与比较
Int J Gynecol Cancer. 2023 Feb 6;33(2):263-270. doi: 10.1136/ijgc-2022-003998.
7
Nomogram to predict postoperative complications after cytoreductive surgery for advanced epithelial ovarian cancer: A multicenter retrospective cohort study.预测晚期上皮性卵巢癌肿瘤细胞减灭术后并发症的列线图:一项多中心回顾性队列研究
Front Oncol. 2022 Nov 23;12:1052628. doi: 10.3389/fonc.2022.1052628. eCollection 2022.
8
Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer.在晚期卵巢癌治疗中,最大程度的手术努力会增加术后并发症的风险。
Eur J Surg Oncol. 2022 Dec;48(12):2525-2530. doi: 10.1016/j.ejso.2022.06.007. Epub 2022 Jun 9.
9
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.主要术后并发症对卵巢癌细胞减灭术后复发和长期生存的影响。
Gynecol Oncol. 2022 Jul;166(1):8-17. doi: 10.1016/j.ygyno.2022.05.002. Epub 2022 May 12.
10
Complications after advanced ovarian cancer surgery-A population-based cohort study.高级卵巢癌手术后的并发症:一项基于人群的队列研究。
Acta Obstet Gynecol Scand. 2022 Jul;101(7):747-757. doi: 10.1111/aogs.14355. Epub 2022 Apr 11.